In the last year, Price for China Regenerative Medicine International has grown by 100.00%, going from HK$0.00 to HK$0.00. In the coming year, analysts are expecting an increase in Fair Value, predicting it will reach HK$0.00 – an increase of 100.00%. Over the next six years, experts anticipate that Fair Value growth for China Regenerative Medicine International will be 100.00%.

2025 Fair Value Forecast

HK$0.00

2026 Fair Value Forecast

HK$0.00

2027 Fair Value Forecast

HK$0.00

2028 Fair Value Forecast

HK$0.00

2029 Fair Value Forecast

HK$0.00

2030 Fair Value Forecast

HK$0.00

China Regenerative Medicine International Revenue Forecast for 2023 - 2025 - 2030

In the last three years, China Regenerative Medicine International's Revenue has decreased by 62.51%, going from HK$185.34M to HK$69.49M. In the coming year, analysts are expecting an increase in Revenue, predicting it will reach HK$120.67M – an increase of 73.65%. Over the next seven years, experts anticipate that Revenue growth for China Regenerative Medicine International will be 247.38%.

2024 Rev Forecast

HK$0.12B

2025 Rev Forecast

HK$0.21B

2026 Rev Forecast

HK$0.31B

2027 Rev Forecast

HK$0.19B

2028 Rev Forecast

HK$0.18B

2029 Rev Forecast

HK$0.20B

2030 Rev Forecast

HK$0.24B

China Regenerative Medicine International Dividend per Share Forecast for 2023 - 2025 - 2030

China Regenerative Medicine International Free Cash Flow Forecast for 2023 - 2025 - 2030

China Regenerative Medicine International EBITDA Forecast for 2023 - 2025 - 2030

In the last three years, China Regenerative Medicine International's EBITDA has decreased from HK$-139.30M to HK$-25.94M – a 81.38% drop! For next year, the 0 analysts predict EBITDA of HK$-46.31M, which would mean an increase of 78.52%. Over the next seven years, the pros' prediction is EBITDAof HK$-116.82M, which would mean a seven-year growth forecast of 350.34%.

2024 EBITDA Forecast

HK$-46308088.00

2025 EBITDA Forecast

HK$-126160211.34

2026 EBITDA Forecast

HK$-142523190.76

2027 EBITDA Forecast

HK$-86107761.08

2028 EBITDA Forecast

HK$-83452771.78

2029 EBITDA Forecast

HK$-99369997.12

2030 EBITDA Forecast

HK$-116819368.61

China Regenerative Medicine International EBIT Forecast for 2023 - 2025 - 2030

In the last three years, China Regenerative Medicine International has seen a decline in its EBIT, from HK$-141.03M to HK$-26.11M – a 81.49% decrease. In the next year, analysts expect EBIT to reach HK$-46.85M – an increase of 79.42%. For the next seven years, the forecast is for EBIT to grow by 354.21%.

2024 EBIT Forecast

HK$-46845691.67

2025 EBIT Forecast

HK$-128485240.06

2026 EBIT Forecast

HK$-144515915.18

2027 EBIT Forecast

HK$-87244257.99

2028 EBIT Forecast

HK$-84632746.54

2029 EBIT Forecast

HK$-100896339.33

2030 EBIT Forecast

HK$-118593557.25

China Regenerative Medicine International EPS Price Prediction Forecast for 2023 - 2025 - 2030

In the last year, EPS for China Regenerative Medicine International has grown by 100.00%, going from HK$-1.80 to HK$0.00. In the coming year, analysts are expecting an increase in EPS, predicting it will reach HK$0.00 – an increase of 100.00%. Over the next six years, experts anticipate that EPS growth for China Regenerative Medicine International will be 100.00%.

2025 EPS Forecast

HK$0.00

2026 EPS Forecast

HK$0.00

2027 EPS Forecast

HK$0.00

2028 EPS Forecast

HK$0.00

2029 EPS Forecast

HK$0.00

2030 EPS Forecast

HK$0.00